CD7 in Acute Myeloid Leukemia: Correlation with Loss of Wild-type CEBPA, Consequence of Epigenetic Regulation

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2010 Apr 20

PMID 20398252

Citations 9

Authors

Sonja Rohrs

Michaela Scherr

Julia Romani

Margarete Zaborski

Hans G Drexler

Hilmar Quentmeier

Affiliations

Soon will be listed here.

Abstract

Background: CD7 is a negative prognostic marker in myeloid malignancies. In acute myeloid leukemia (AML), an inverse correlation exists between expression of wild-type CEBPA and CD7. Aim of this study was to find out whether C/EBPalpha is a negative regulator of CD7 and which other regulatory mechanisms might be involved.

Results: As already described for primary AML cells, the majority of AML cell lines tested were either C/EBPalpha+/CD7- or C/EBPalpha-/CD7+. However, the existence of isolated CD7+ cell lines expressing wild-type C/EBPalpha challenges the notion that C/EBPalpha acts as a unique repressor of CD7. Furthermore, ectopic expression of CEBPA did not reduce CD7 in CD7+ cells and knock-down of C/EBPalpha failed to induce CD7 in CD7- cells. In contrast, the DNA demethylating agent Aza-2'deoxycytidine triggered CD7 expression in CD7- AML and in T-cell lines suggesting epigenetic regulation of CD7. Bisulfite sequencing data confirmed that CpGs in the CD7 exon1 region are methylated in CD7- cell lines, and unmethylated in CD7+ cell lines.

Conclusion: We confirmed an inverse correlation between the expression of wild-type CEBPA and of CD7 in AML cells. Our results contradict the hypothesis that C/EBPalpha acts as repressor for CD7, and instead show that epigenetic mechanisms are responsible for CD7 regulation, in AML cells as well as in T-cells, the typical CD7 expressing cell type.

Citing Articles

Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.

Jen W, Sasaki K, Loghavi S, Wang S, Qiao W, Borthakur G Br J Haematol. 2024; 204(6):2259-2263.

PMID: 38603594 PMC: 11770636. DOI: 10.1111/bjh.19446.

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC.

Yi J, Shuang Z, Zhong W, Wu H, Feng J, Zouxu X Front Genet. 2021; 12:730442.

PMID: 34777466 PMC: 8586457. DOI: 10.3389/fgene.2021.730442.

Prognostic Prediction of Cytogenetically Normal Acute Myeloid Leukemia Based on a Gene Expression Model.

Yang L, Zhang H, Yang X, Lu T, Ma S, Cheng H Front Oncol. 2021; 11:659201.

PMID: 34123815 PMC: 8190396. DOI: 10.3389/fonc.2021.659201.

[CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA].

Zhu M, Zhu Y, Chen R, Zhu L, Zhu J, Li X Zhonghua Xue Ye Xue Za Zhi. 2020; 41(2):100-105.

PMID: 32135624 PMC: 7357943. DOI: 10.3760/cma.j.issn.0253-2727.2020.02.003.

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond.

Epperly R, Gottschalk S, Velasquez M Children (Basel). 2020; 7(2).

PMID: 32079207 PMC: 7072334. DOI: 10.3390/children7020014.

References

Johansen L, Iwama A, Lodie T, Sasaki K, Felsher D, Golub T . c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 2001; 21(11):3789-806. PMC: 87031. DOI: 10.1128/MCB.21.11.3789-3806.2001. View

Mueller B, Pabst T . C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol. 2005; 13(1):7-14. DOI: 10.1097/01.moh.0000190110.08156.96. View

Lin L, Chen C, Lin D, Tsay W, Tang J, Yeh Y . Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005; 11(4):1372-9. DOI: 10.1158/1078-0432.CCR-04-1816. View

Iwama A, Zhang P, Darlington G, McKercher S, Maki R, Tenen D . Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha. Nucleic Acids Res. 1998; 26(12):3034-43. PMC: 147647. DOI: 10.1093/nar/26.12.3034. View

Radomska H, Huettner C, Zhang P, Cheng T, Scadden D, Tenen D . CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998; 18(7):4301-14. PMC: 109014. DOI: 10.1128/MCB.18.7.4301. View

Satoh C, Tamura H, Yamashita T, Tsuji T, Dan K, Ogata K . Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. Leuk Res. 2008; 33(2):326-31. DOI: 10.1016/j.leukres.2008.07.006. View

Rogers S, Zhao Y, Jiang X, Eaves C, Mager D, Rouhi A . Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia. Mol Cancer. 2010; 9:41. PMC: 2843654. DOI: 10.1186/1476-4598-9-41. View

Quentmeier H, Schneider B, Rohrs S, Romani J, Zaborski M, MacLeod R . SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. 2009; 2:3. PMC: 2636835. DOI: 10.1186/1756-8722-2-3. View

Pabst T, Mueller B, Zhang P, Radomska H, Narravula S, Schnittger S . Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001; 27(3):263-70. DOI: 10.1038/85820. View

10.

Gardiner-Garden M, Frommer M . CpG islands in vertebrate genomes. J Mol Biol. 1987; 196(2):261-82. DOI: 10.1016/0022-2836(87)90689-9. View

11.

Wouters B, Alberich Jorda M, Keeshan K, Louwers I, Erpelinck-Verschueren C, Tielemans D . Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007; 110(10):3706-14. PMC: 2077318. DOI: 10.1182/blood-2007-02-073486. View

12.

Chang H, Salma F, Yi Q, Patterson B, Brien B, Minden M . Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2003; 28(1):43-8. DOI: 10.1016/s0145-2126(03)00180-2. View

13.

Scherr M, Battmer K, Ganser A, Eder M . Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle. 2003; 2(3):251-7. View

14.

Weber M, Hellmann I, Stadler M, Ramos L, Paabo S, Rebhan M . Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007; 39(4):457-66. DOI: 10.1038/ng1990. View

15.

Oelgeschlager M, Nuchprayoon I, Luscher B, Friedman A . C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol. 1996; 16(9):4717-25. PMC: 231472. DOI: 10.1128/MCB.16.9.4717. View

16.

Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T . BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005; 21(21):4067-8. DOI: 10.1093/bioinformatics/bti652. View

17.

Smith L, Hohaus S, Gonzalez D, Dziennis S, Tenen D . PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood. 1996; 88(4):1234-47. View